KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of merkel cell carcinoma in vitro

Journal of Cellular Physiology

Volumn 226, Issue 4, 2011, Pages 1099-1109

  Krasagakis, Konstantin ^a   Fragiadaki, Irene ^a   Metaxari, Maria ^a   Krüger Krasagakis, Sabine ^a   Tzanakakis, George N ^a   Stathopoulos, Efstathios N ^a   Eberle, Jürgen ^b   Tavernarakis, Nektarios ^c   Tosca, Androniki D ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; IMATINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUTRALIZING ANTIBODY; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; WORTMANNIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; BINDING SITE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; IN VITRO STUDY; MERKEL CELL TUMOR; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIBODIES, NEUTRALIZING; AUTOCRINE COMMUNICATION; CARCINOMA, MERKEL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PARACRINE COMMUNICATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SOLUBILITY; STEM CELL FACTOR;

EID: 79251469051     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22431     Document Type: Article

References (55)

1. Bellone G, Carbone A, Sibona N, Bosco O, Tibaudi D, Smirne C, Martone T, Gramigni C, Camandona M, Emanuelli G, Rodeck U. 2001 Aberrant activation of c-kit protects colon carcinoma cells against apoptosis and enhances their invasive potential. Cancer Res 61:2200-2206.
2. Blume-Jensen P, Janknecht R, Hunter T. 1998. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr Biol 8:779-782.
3. Brunner M, Thurnher D, Pammer J, Geleff S, Heiduschka G, Reinisch CM, Petzelbauer P, Erovic BM. 2008. Expression of VEGF-A/C, VEGF-R2, PDGF-alpha/beta, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma. Mod Pathol 21:876-884.
4. Feng H, Shuda M, Chang Y, Moore PS. 2008. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319:1096-1100.
5. Fenig E, Nordenberg J, Beery E, Sulkes J, Wasserman L. 2004. Combined effect of aloe-emodin and chemotherapeutic agents on the proliferation of an adherent variant cell line of Merkel cell carcinoma. Oncol Rep 11:213-217.
6. Foster R, Byrnes E, Meldrum C, Griffith R, Ross G, Upjohn E, Braue A, Scott R, Varigos G, Ferrao P, Ashman LK. 2008. Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT. Br J Dermatol 159:1160-1169.
7. Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Böhm A, Gruze A, Samorapoompichit P, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P. 2006. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: Comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107:752-759.
8. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. 2000. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925-932.
9. Hikono H, Zhou JH, Ohta M, Inumaru S, Momotani E, Sakurai M. 2002. Production of a monoclonal antibody that recognizes bovine stem cell factor (SCF) and its use in the detection and quantitation of native soluble bovine SCF in fetal bovine serum. J Interferon Cytokine Res 22:231-235.
10. Hirano K, Shishido-Hara Y, Kitazawa A, Kojima K, Sumiishi A, Umino M, Kikuchi F, Sakamoto A, Fujioka Y, Kamma H. 2008. Expression of stem cell factor (SCF), a KIT ligand, in gastrointestinal stromal tumors (GISTs): A potential marker for tumor proliferation. Pathol Res Pract 204:799-807.
11. Hitchcock CL, Bland KI, Laney RG III, Franzini D, Harris B, Copeland EM III. 1988. Neuroendocrine (Merkel cell) carcinoma of the skin. Its natural history, diagnosis, and treatment. Ann Surg 207:201-207.
12. Hornick JL, Fletcher CD. 2007. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 38:679-687.
13. Houben R, Michel B, Vetter-Kauczok CS, Pföhler C, Laetsch B, Wolter MD, Leonard JH, Trefzer U, Ugurel S, Schrama D, Becker JC. 2006. Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma. J Invest Dermatol 126:1135-1142.
14. Houben R, Ortmann S, Schrama D, Herold MJ, Berberich I, Reichardt HM, Becker JC. 2007. Activation of the MAP kinase pathway induces apoptosis in the Merkel cell carcinoma cell line UISO. J Invest Dermatol 127:2116-2122.
15. Inokuchi K, Yamaguchi H, Tarusawa M, Futaki M, Hanawa H, Tanosaki S, Dan K. 2002. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia-potential clinical significance. Leukemia 16:170-177.
16. Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, Gartel A, Hay N. 2002. Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol 22:7831-7841.
17. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. 2006. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542-2551.
18. Kartha RV, Sundram UN. 2008. Silent mutations in KIT and PDGFRA and coexpression of receptors with SCF and PDGFA in Merkel cell carcinoma: Implications for tyrosine kinase-based tumorigenesis. Mod Pathol 21:96-104.
19. Krasagakis K, Almond-Roesler B, Zouboulis CC, Tebbe B, Wartenberg E, Wolff KD, Orfanos CE. 1997. Merkel cell carcinoma: Report of ten cases with emphasis on clinical course, treatment, and in vitro drug sensitivity. J Am Acad Dermatol 36:727-732.
20. Krasagakis K, Almond-Roesler B, Geilen C, Fimmel S, Krengel S, Chatzaki E, Gravanis A, Orfanos CE. 2001. Growth and characterization of a cell line from a human primary neuroendocrine carcinoma of the skin (Merkel cell carcinoma) in culture and as xenograft. J Cell Physiol 187:386-391.
21. Krasagakis K, Krüger-Krasagakis S, Tzanakakis GN, Darivianaki K, Stathopoulos EN, Tosca AD. 2008. Interferon-alpha inhibits proliferation and induces apoptosis of Merkel cell carcinoma in vitro. Cancer Invest 26:562-568.
22. Krasagakis K, Krüger-Krasagakis S, Eberle J, Tsatsakis A, Tosca AD, Stathopoulos EN. 2009. Co-expression of KIT receptor and its ligand stem cell factor in Merkel cell carcinoma. Dermatology 218:37-43.
23. Krüger-Krasagakes S, Krasagakis K, Garbe C, Schmitt E, Hüls C, Blankenstein T, Diamantstein T. 1994. Expression of interleukin 10 in human melanoma. Br J Cancer 70:1182-1185.
24. Krystal GW, Hines SJ, Organ CP. 1996. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 56:370-376.
25. Krystal GW, Honsawek S, Litz J, Buchdunger E. 2000. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6:3319-3326.
26. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y, IRIS (International Randomized Interferon vs STI571) Study Group. 2008. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of the IRIS study. Blood 111:4022-4028.
27. Lassacher A, Heitzer E, Kerl H, Wolf P. 2008. p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in Merkel cell carcinoma. J Invest Dermatol 128:1788-1796.
28. Longley BJ, Jr., Morganroth GS, Tyrrell L, Ding TG, Anderson DM, Williams DE, Halaban R. 1993. Altered metabolism of mast-cell growth factor (KIT ligand) in cutaneous mastocytosis. N Engl J Med 328:1302-1307.
29. Miettinen M, Lasota J. 2005. KIT (CD117): A review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 13:205-220.
30. Miyazawa K, Toyama K, Gotoh A, Hendrie PC, Mantel C, Broxmeyer HE. 1994. Ligand-dependent polyubiquitination of c-kit gene product: A possible mechanism of receptor down modulation in M07e cells. Blood 83:137-145.
31. Miyazawa K, Williams DA, Gotoh A, Nishimaki J, Broxmeyer HE, Toyama K. 1995. Membrane-bound Steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. Blood 85:641-649.
32. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou H, Sang BC, Wilson KP. 2004. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279:31655-31663.
33. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD. 1995. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 92:10560-10564.
34. Pandiella A, Carvajal-Vergara X, Tabera S, Mateo G, Gutiérrez N, San Miguel JF. 2003. Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. Br J Haematol 123:858-868.
35. Plettenberg A, Pammer J, Tschachler E. 1996. Merkel cells and Merkel cell carcinoma express the BCL-2 proto-oncogene. Exp Dermatol 5:183-188.
36. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, Sellers WR. 1999. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96:2110-2115.
37. Ratajczak MZ, Luger SM, DeRiel K, Abrahm J, Calabretta B, Gewirtz AM. 1992. Role of the KIT protooncogene in normal and malignant human hematopoiesis. Proc Natl Acad Sci USA 89:1710-1714.
38. Roberts KG, Odell AF, Byrnes EM, Baleato RM, Griffith R, Lyons AB, Ashman LK. 2007. Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther 6:1159-1166.
39. Roskoski R Jr. 2005. Signaling by Kit protein-tyrosine kinase-The stem cell factor receptor. Biochem Biophys Res Commun 337:1-13.
40. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA. 2001. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118-8121.
41. Samlowski WE, Moon J, Tuthill RJ, Heinrich MC, Balzer-Haas NS, Merl SA, Deconti RC, Thompson JA, Witter MT, Flaherty LE, Sondak VK. 2009. A Phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group Study (S0331). Am J Clin Oncol DOI:10.1097/COC.0b013e3181b9cf04.
42. Schlüter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, Gerdes J. 1993. The cell proliferation-associated antigen of antibody Ki-67: A very large, ubiquitus nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 123:513-522.
43. Scott RJ, Hall PA, Haldane JS, van Noorden S, Price Y, Lane DP, Wright NA. 1991. A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol 165:173-178.
44. Serve H, Hsu YC, Besmer P. 1994. Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. J Biol Chem 269:6026-6030.
45. Su LD, Fullen DR, Lowe L, Uherova P, Schnitzer B, Valdez R. 2002. CD117 (KIT receptor) expression in Merkel cell carcinoma. Am J Dermatopathol 24:289-293.
46. Swick BL, Ravdel L, Fitzpatrick JE, Robinson WA. 2007. Merkel cell carcinoma: Evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene-Implications for treatment with imatinib mesylate. J Cutan Pathol 34:324-329.
47. Théou-Anton N, Tabone S, Brouty-Boyé D, Saffroy R, Ronnstrand L, Lemoine A, Emile JF. 2006. Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism. Br J Cancer 94:1180-1185.
48. Turner AM, Bennett LG, Lin NL, Wypych J, Bartley TD, Hunt RW, Atkins HL, Langley KE, Parker V, Martin F, Broudy VC. 1995. Identification and characterization of a soluble c-kit receptor produced by human hematopoietic cell lines. Blood 85:2052-2058.
49. Uberla K, Platzer C, Diamantstein T, Blankenstein T. 1991. Generation of competitor DNA fragments for quantitative PCR. Genome Res 1:136-139.
50. Ueda S, Mizuki M, Ikeda H, Tsujimura T, Matsumura I, Nakano K, Daino H, Honda Zi Z, Sonoyama J, Shibayama H, Sugahara H, Machii T, Kanakura Y. 2002. Critical roles of c-Kit tyrosine residues 567 and 719 in stem cell factor-induced chemotaxis: Contribution of src family kinase and PI3-kinase on calcium mobilization and cell migration. Blood 99:3342-3349.
51. Van Gele M, Kaghad M, Leonard JH, Van Roy N, Naeyaert JM, Geerts ML, Van Belle S, Cocquyt V, Bridge J, Sciot R, De Wolf-Peeters C, De Paepe A, Caput D, Speleman F. 2000. Mutation analysis of P73 and TP53 in Merkel cell carcinoma. Br J Cancer 82:823-826.
52. Verstovsek S, Akin C, Manshouri T, Quintás-Cardama A, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ, Kantarjian H. 2006. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 30:1365-1370.
53. Wypych J, Bennett LG, Schwartz MG, Clogston CL, Lu HS, Broudy VC, Bartley TD, Parker VP, Langley KE. 1995. Soluble kit receptor in human serum. Blood 85:66-73.
54. Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR, Modlin RL. 1991. Defining protective responses to pathogens: Cytokine profiles in leprosy lesions. Science 254:277-279.
55. Yarden Y, Kuang W-J. Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A. 1987. Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6:3341-3351.